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Abstract
Background: Among low-income women with and without HIV, it is a priority to reduce age-related co-
morbidities, including hypertension and its sequelae. Because consistent health insurance access has been
identified as an important factor in controlling many chronic diseases, we estimated the effects of coverage
interruption on loss of hypertension control in a cohort of women in the United States.
Methods: We analyzed prospective, longitudinal data from the Women’s Interagency HIV Study. HIV-infected
and HIV-uninfected women were included between 2005 and 2014 when they reported health insurance at
consecutive biannual visits and had controlled hypertension, and were followed for any insurance break and loss
of hypertension control. We estimated hazard ratios (HRs) by Cox proportional hazards regression with inverse-
probability-of-treatment-and censoring weights (marginal structural models), and plotted the cumulative inci-
dence of hypertension control loss.
Results: Among 890 HIV-infected women, the weighted HR for hypertension control loss comparing health
insurance interruption to uninterrupted coverage was 1.37 (95% confidence interval [CI], 0.99–1.91). Inclusion
of AIDS Drug Assistance Program (ADAP) participation with health insurance modestly increased the HR
(1.47; 95% CI, 1.04–2.07). Analysis of 272 HIV-uninfected women yielded a similar HR (1.39; 95% CI, 0.88–
2.21). Additionally, there were indications of uninterrupted coverage having a protective effect on hypertension
when compared with the natural course in HIV-infected (HR, 0.82; 95% CI, 0.61–1.11) and HIV-uninfected
(HR, 0.78; 95% CI, 0.52–1.19) women.
Conclusions: This study provides evidence that health insurance continuity promotes hypertension control in
key populations. Interventions that ensure coverage stability and ADAP access should be a policy priority.
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Introduction
As women with HIV are living longer,
1 it is a priority to
determine ways to reduce their age-related comorbid-
ities, including hypertension and its sequelae. For low-
income HIV-uninfected women, who have poorer health than
higher income women,2 the consequences of these co-
morbidities may be even greater. One method of improving
health is increasing the proportions of populations with health
insurance, which is associated with positive health-related
outcomes among both HIV-infected and low-income indi-
viduals in the United States (US).3–5
Among persons with HIV, lack of health insurance has
been associated with delayed HIV care6 and failure to enter
care,7 and having insurance has been related to decreases in
HIV-related mortality.3 Continuous health insurance cover-
age has strong, positive effects on antiretroviral therapy
(ART) use and ambulatory care.5 Interruptions in coverage
have been associated with ART discontinuation,8 and chan-
ges in insurance have been linked to decreased ART use.9
Despite increases in health insurance access, *30% of HIV-
infected persons in the US were uninsured in 2013.10
Low-income HIV-uninfected women may be even less
likely to have coverage and receive healthcare than HIV-
infected women.11 This is likely due, in part, to not having
access to specialized programs such as the Ryan White HIV/
AIDS Program, which supports services, including medica-
tion assistance, through the AIDS Drug Assistance Program
(ADAP).12 Millions of low-income individuals lack coverage
because their incomes are above the Medicaid eligibility limit
but below the limit for Marketplace premium tax credits.13
Being low-income and uninsured are each linked to not
having a regular provider, cost-related access problems, un-
derutilization of preventive services, and lower healthcare
quality.14 Although expanding public health insurance access
for low-income adults has beneficial effects on healthcare
access and use, financial strain, and health,4 Medicaid in-
terruptions (e.g., dropout or eligibility loss) are frequent15,16
and linked to higher hospitalization rates for outpatient-
manageable conditions.17
High blood pressure (BP) can lead to coronary heart dis-
ease, heart failure, kidney failure, and stroke.18 The co-
occurrence of hypertension and HIV is of growing concern
not only because of ART-driven increasing life expectancy
on a population level but also because of high cardiovascular
risk possibly due to HIV and ART19 and evidence of higher
myocardial infarction rates in HIV-infected persons.20,21
Poor hypertension control has been noted in HIV-infected
cohorts,22,23 with increased BP associated with cardiovascular
events.24 Hypertension is also a crucial issue for low-income
HIV-uninfected women, given the association between low
socioeconomic status and hypertension25 as well as poverty’s
associations with lack of access to healthcare14 and insur-
ance,26,27 both of which are essential to obtain antihyperten-
sive medications and avert negative outcomes.
We prospectively evaluated the effects of health insurance
interruption on loss of hypertension control among low-
income US women with or at risk for HIV infection in the
Women’s Interagency HIV Study (WIHS), as to our knowl-
edge there has been no prior research on this relationship




Our data source was the WIHS, a multisite US cohort,
including both HIV-infected women and HIV-uninfected
women at risk for HIV infection, specifically designed to
allow the evaluation of topical research questions across and
within these populations. The presence of HIV-infected and
HIV-uninfected women in the cohort was a reason it was
selected to pursue the study aims. WIHS visits are conducted
biannually and consist of a clinical examination, specimen
collection, and an interview to obtain self-reported medical
history, medication use, and sociodemographic information.
While age and other eligibility criteria for the WIHS have
evolved across four waves of enrollment, women ‘‘at risk’’
for HIV have generally been defined as reporting at least one
of the following criteria during the past year: having sex with
a man with known HIV infection; having sex with six or more
men, having condomless sex with three or more men; having
sex for drugs, money, or shelter; diagnosis by a healthcare
provider with a sexually transmitted disease; using crack, co-
caine, heroin, methamphetamine, or injection drugs.28 Further
details on participant recruitment, retention, and characteris-
tics have been previously reported.29,30
HIV-infected and HIV-uninfected women were analyzed
separately and included at their first study visit (from October
2005 to March 2006 WIHS visit window or during a later 6-
month window, but no later than the October 2013 to March
2014 window) with stable health insurance and controlled
hypertension, if they attended at least one visit after this
‘‘analysis baseline.’’ This period was chosen as the earliest
possible baseline because it corresponds approximately to
the beginning of the modern ART era, examined in a re-
cent WIHS of health insurance and HIV suppression,31 and
shortly follows the release and implementation of updated
hypertension definition and treatment guidelines.32
Follow-up began at the ‘‘analysis baseline’’ and ended at
the first occurrence of uncontrolled hypertension (systolic BP
‡140 [mmHg] or diastolic BP ‡90), censoring (death date or
two consecutive missed visits), or administrative censoring
after the April 2014 to September 2014 visit. All women
meeting the inclusion criteria were analyzed; no sampling
scheme was used to select study participants.
Specification of health insurance
Stable health insurance at baseline was defined as self-
reported health insurance for at least two consecutive at-
tended study visits. Health insurance was classified into four
mutually exclusive groups similar to those described by the
Kaiser Family Foundation,33 with categories assigned in this
order: Medicaid, private or student, Medicare or other public
(including Tricare/CHAMPUS, Veteran’s Administration,
and city/county), and no health insurance. Categories were
then collapsed into any or no coverage.
Group A included HIV-infected women with stable health
insurance coverage at baseline who may or may not also have
participated in ADAP. For Group A, loss of coverage (the
exposure) was defined solely as loss of insurance, regardless
of ADAP participation.
Because HIV-infected individuals who lack health in-
surance but report ADAP participation may be closer to
functionally insured than uninsured, we also developed an
additional specification, Group B, which included HIV-
infected women who at baseline had stable health insurance
alone, ADAP coverage alone, or both health insurance and
ADAP coverage. Loss of coverage for Group B was defined
having neither health insurance nor ADAP protection after
the baseline visit.
Group C included HIV-uninfected women with stable
health insurance coverage at baseline; this population is not
eligible for ADAP, so loss of coverage for them was simply
defined as loss of health insurance after the baseline visit. A
flowchart detailing participant selection is depicted in Figure 1.
Ascertainment of hypertension
Controlled hypertension was defined as systolic BP
<140 mmHg and diastolic BP <90 mmHg following previous
documentation of hypertension, defined as antihypertensive
medication use or at least two WIHS visits with systolic
BP ‡140 or diastolic BP ‡90. One visit with systolic BP <140
and diastolic BP <90 was sufficient to establish controlled
hypertension.
Starting in 2004, three BP measurements per visit were
taken, with the mean of the second and third measurements
used. Between 2001 and 2004, staff measured each partici-
pant’s BP twice; the second measurement was used unless the
readings differed in their systolic or diastolic values by more
than 80 and 45 mmHg, respectively, in which case the higher
measurement was used. Before 2001, BP was measured only
once. BP measurements were collected from the right arm of
a seated participant using an automated Dinamap blood
pressure monitor (DinaMap ProCare Series; GE Medical
Systems, Chicago, IL).28 The monitor automatically measured
BP at 1-minute intervals following a 5-minute period of sitting
quietly without talking. The clinician was in the room during
BP measurement and passively raised the participant’s arm
overhead for the first 5 seconds between each measurement.
Covariates and definitions
To identify possible confounders, we constructed causal
diagrams.34 Baseline confounders (reference levels marked
by asterisk) were site (Brooklyn or Bronx,* Chicago, San
Francisco, Los Angeles, Washington, D.C.), race (African
American,* white, other), age, CD4 count, and HIV viral
load. Time-varying confounders affected by prior exposure
were annual household income (<$6,000, $6,001–$12,000,*
$12,001–$18,000, >$18,000), body mass index, and in HIV-
infected women only, CD4 count and HIV viral load.
Other considered confounders (e.g., depression, employ-
ment, drug/alcohol/tobacco use) that decreased preci-
sion while negligibly changing parameter estimates were
not included.
Nominal covariates were coded as disjoint indicator vari-
ables, with continuous variables specified as splines. Un-
detectable HIV viral load measurements were assigned half
the lower detection limit.35 If data were missing, prior visit
values were used; no baseline confounder had >1.5% of
missing values and no time-varying confounder was missing
at >5.7% of observed visits. The definition of ART followed
DHHS guidelines.36
Statistical analysis
Proportions were compared using the chi-square test, with
a Wilcoxon nonparametric test for location used to compare
medians.37 For modeling analyses, the exposure variable
switched from ‘‘coverage’’ (i.e., unexposed; by definition,
women had coverage at baseline) to ‘‘no coverage’’ (i.e.,
exposed) at the first postbaseline visit that a woman reported
loss of coverage. This status change is synonymous with a
coverage break/interruption; once a woman’s status switched
to ‘‘no coverage,’’ she was classified as having a break/in-
terruption until the end of follow-up. Because we hypothe-
sized that the consequences of coverage interruption may be
FIG. 1. Participant selection flowchart: Groups A, B, and C.
temporally limited, we did a sensitivity analysis where
follow-up was censored 3 years following a break.
Our primary aim was to estimate the total effect of cov-
erage interruption on loss of hypertension control, which
requires adjustment not only for baseline confounders but
also for time-varying confounders affected by prior exposure
(causal intermediates between coverage status and loss of
hypertension control). This was accomplished by using lo-
gistic regression to predict probabilities of (a) treatment
(i.e., exposure) and (b) censoring based on covariate histories
(i.e., past and current data), and constructing stabilized
inverse-probability-of-treatment-and-censoring weights.38
We weighted by baseline and time-varying confounders
affected by prior exposure and stabilized by baseline con-
founders. Models for the censoring weights additionally in-
cluded time-varying health insurance, and all models
included time specified as a restricted cubic spline with four
knots at the 5th, 35th, 65th, and 95th percentiles.39
Assuming positivity, consistency, and no model mis-
specification, unmeasured confounding, or informative cen-
soring, weighting creates a pseudo population in which
exposure is independent from measured confounders.40
Therefore, if women had continuous coverage before inter-
ruption was reported (reasonable as status was assessed
biannually), the weighted hazard ratio (HR) estimates the
parameter from a randomized trial, contrasting the hazard
of hypertension control loss had all women experienced a
coverage interruption at baseline to the hazard had all women
had continuous coverage throughout follow-up. Our use of
stabilized weights necessitated inclusion of baseline con-
founders in the marginal structural model.41
Proportionality of hazards was verified by visual inspec-
tion of log-negative-log survival estimates. In addition, the
complements of weighted survivor functions were plotted as
estimates of the cumulative incidence of hypertension control
loss for (a) uninterrupted coverage and (b) coverage inter-
ruption, since baseline. We also compared uninterrupted
coverage to the natural course (i.e., what was actually ob-
served),42 the contrast most relevant to policies or interven-
tions that prevent coverage breaks.
Analyses were conducted using SAS version 9.4 (SAS
Institute, Inc., Cary, NC). All women consented to WIHS
participation, with consent obtained by trained study per-
sonnel at clinic sites, and agreed to contribute their data
to research. Approval was granted by relevant institutional
review boards.
Results
Of the total 3,143 HIV-infected WIHS participants, 1,558
(49.6%) had stable health insurance at the baseline visit, of
whom 952 (61.1%) had prior hypertension, of whom 908
(95.4%) had concurrent controlled hypertension and stable
health insurance, of whom 842 (92.7%) attended at least one
visit after baseline (Fig. 1). These 842 women comprised
Group A. Most enrolled in either 1994–1995 (n = 534, 63.4%)
or 2001–2002 (n = 224, 26.6%) (Table 1). The proportion of
the population contributed from any WIHS site ranged from
11.3% (Los Angeles) to 21.5% (Bronx). Over two-thirds of
women were African American (n = 575, 68.3%), with 145
(17.2%) white and 122 (14.5%) other. The highest level of
educational attainment was roughly split between less than
(n = 318, 37.8%), equal to (n = 253, 30.1%), and greater than
high school (n = 270, 32.1%).
At baseline, the median age was 47.7 years with an inter-
quartile range (IQR) of 42.4–52.4. Overall, the women were
low-income; approximately half had annual household in-
comes of $12,000 or less (n = 457, 53.4%) with less than a
third exceeding $18,000 (n = 267, 31.7%). Accordingly, most
women received Medicaid (n = 647, 76.8%) with a minority
having private health insurance (n = 155, 18.4%); few had
Medicare or other public coverage (n = 38, 4.5%). Almost
half had a prior AIDS diagnosis (n = 369, 43.8%). Most were
receiving ART (n = 638, 75.8%), and about half had an un-
detectable HIV viral load (n = 448, 53.2%). Median CD4
count was 497 cells/mm3 (IQR, 308–715).
These 842 women contributed 2125.5 person-years (me-
dian, 1.6 years; IQR, 0.8–3.6) and attended 5,030 study visits
(median, four visits; IQR, 2–8), approximately two per
person-year reflecting the biannual visit schedule (Table 1).
The relatively short median duration of follow-up per woman
was a consequence of most women (n = 569, 67.6%) expe-
riencing hypertension control loss (Fig. 2); 89 women
(10.6%) were censored due to missed visits or death and 184
(21.9%) maintained controlled hypertension. Therefore,
the overall rate of hypertension control loss was high at
26.8 per 100 person-years, with a 95% confidence interval
(CI) of 24.6–29.1. Few women (n = 73, 8.7%) experienced
coverage interruption (Fig. 2), with similar proportions
of total person-time (8.3%) and outcomes (n = 46, 8.1%)
occurring postinterruption.
Of the postinterruption person-time, 35.9% were unin-
sured (i.e., some women regained coverage following the
break). The median systolic and diastolic BP at visits where
insurance was reported were 119 (IQR, 110–130) and 74
(IQR, 68–80), respectively, similar to the median systolic
(121.5; IQR, 112–134) and diastolic (76; IQR, 68–84) values
at visits where no insurance was reported. When the ‘‘health
insurance or ADAP’’ definition of coverage was used (Group
B), a similar number of women (n = 890) were eligible (Fig. 1).
This minor change to the inclusion criteria resulted in no no-
table changes to the baseline composition of the study popu-
lation or its experiences during follow-up; only 70 women
(7.9%) had no coverage besides ADAP at baseline.
Among HIV-infected women when the coverage definition
did not include ADAP (Group A), the crude Cox proportional
hazards model suggested a greater hazard of hypertension
control loss (HR, 1.29, 95% CI, 0.95–1.75), given coverage
interruption compared to uninterrupted coverage (Table 2).
The HRs were slightly further from the null in the weighted
model (HR, 1.37, 95% CI, 0.99–1.91) and when follow-up
was censored 3 years postinterruption (HR, 1.42, 95% CI,
1.00–2.02). Among HIV-infected women when coverage
included ADAP (Group B), the trend across the three models
was the same although each of the measures was mod-
estly stronger, increasing from the crude (HR, 1.40; 95% CI,
1.01–1.94) to the weighted (HR, 1.47; 95% CI, 1.04–2.07) to
the weighted with follow-up censored (HR, 1.53; 95% CI,
1.04–2.23).
The cumulative incidences of hypertension control loss
were estimated given the scenarios of (a) uninterrupted cov-
erage and (b) coverage interruption, since baseline (Fig. 3). In
Groups A and B, the cumulative incidence of hypertension
control loss given coverage interruption at baseline was
Table 1. Characteristics and Outcomes of Women with Controlled Hypertension










n = 842 n = 890 n = 272
Baseline
Age in years, median (IQR) 47.7 (42.4–52.4) 47.6 (42.0–52.3) 47.3 (41.6–52.8)
Race, n (%)
African American 575 (68.3) 587 (66.0) 193 (71.0)
White 145 (17.2) 162 (18.2) 38 (14.0)
Other 122 (14.5) 141 (15.8) 41 (15.1)
Site, n (%)
Bronx 181 (21.5) 181 (20.3) 81 (29.8)
Brooklyn 164 (19.5) 168 (18.9) 44 (16.2)
Washington, D.C. 126 (15.0) 129 (14.5) 39 (14.3)
Los Angeles 95 (11.3) 127 (14.3) 32 (11.8)
San Francisco 138 (16.4) 140 (15.7) 47 (17.3)
Chicago 138 (13.4) 145 (16.6) 29 (10.7)
CD4 count, cells/mm3, median (IQR) 497 (308–715) 495 (307–714) N/A
HIV viral load, copies/mL, median (IQR) 40 (40–1,700) 40 (40–1,300) N/A
Receiving ART, n (%) 638 (75.8) 684 (76.9) N/A
Prior AIDS, n (%) 369 (43.8) 381 (42.8) N/A
Systolic blood pressure, mmHg, median (IQR) 119 (111–129) 119 (111–129) 124 (114–131.5)
Diastolic blood pressure, mmHg, median (IQR) 75 (69–81) 74 (68–81) 75 (69–82)
BMI, median (IQR) 28.8 (24.2–34.7) 29.1 (24.5–34.8) 33.3 (28.0–39.3)
Annual household income, n (%)
<$6,000 117 (13.9) 131 (14.7) 58 (21.3)
$6,001–$12,000 340 (40.4) 349 (39.2) 83 (30.5)
$12,001–$18,000 118 (14.0) 130 (14.6) 37 (13.6)
>$18,000 267 (31.7) 280 (31.5) 94 (34.6)
Education, n (%)a
Less than high school 318 (37.8) 343 (38.6) 98 (36.2)
High school 253 (30.1) 266 (29.9) 93 (34.3)
More than high school 270 (32.1) 280 (31.5) 80 (29.5)
Health insurance type, n (%)
Medicaid 647 (76.8) 632 (71.0) 183 (67.3)
Private 155 (18.4) 149 (16.7) 63 (23.2)
Medicare 25 (3.0) 25 (2.8) 11 (4.0)
Other public 13 (1.5) 12 (1.3) 10 (3.7)
Not categorizable 2 (0.2) 2 (0.2) 5 (1.8)
ADAP only 0 (0.0) 70 (7.9) 0 (0.0)
ADAP, n (%) 111 (13.2) 174 (19.6) N/A
Follow-up
Visits, n; median (IQR) 5,030; 4 (2–8) 5,362; 4 (2–8) 1,498; 4 (2–7)
Systolic blood pressure, mmHg, median (IQR) 119 (110–131) 119 (110–131) 122 (112–133)
Diastolic blood pressure, mmHg, median (IQR) 73 (68–80) 73 (68–80) 75 (69–81)
Health insurance interruption, n (%)b 73 (8.7) 58 (6.5) 40 (14.7)
Person-years, n 2125.5 2270.3 620.4
Median (IQR) 1.6 (0.8–3.6) 1.6 (0.8–3.6) 1.5 (0.6–3.1)
Before interruption (%) 1949.1 (91.7) 2129.6 (93.8) 528.1 (85.1)
After interruption (%) 176.4 (8.3) 140.7 (6.2) 92.3 (14.9)
Outcome, n (%)
Censored due to missed visits or death 89 (10.6) 101 (11.3) 22 (8.1)
Active at end of follow-up 184 (21.9) 189 (21.2) 45 (16.5)
Loss of hypertension control 569 (67.6) 600 (67.4) 205 (75.4)
Before interruption (%) 523 (91.9) 561 (93.5) 176 (85.9)
After interruption (%) 46 (8.1) 39 (6.5) 29 (14.1)
aData missing on one woman in each HIV-infected group and on one HIV-uninfected woman.
bDefined as absence of health insurance and absence of ADAP for ‘‘HIV-infected, health insurance, or ADAP’’ group.
ADAP, AIDS Drug Assistance Program; ART, antiretroviral therapy; BMI, body mass index; IQR, interquartile range; N/A, not
applicable; WIHS, Women’s Interagency HIV Study.
higher than given the natural course (not shown because
curves were nearly coincident with, although slightly higher
than, uninterrupted coverage). For scenarios (a) and (b), the
6-year cumulative incidences were 77.6% (95% CI, 71.6–
82.4) and 85.3% (95% CI, 76.3–90.8) in Group A, and 77.4%
(95% CI, 71.5–82.1) and 89.0% (95% CI, 80.1–94.0) in
Group B. Comparing uninterrupted coverage to the natural
course, the HRs (95% CI) in Groups A and B were 0.82
(0.61–1.11) and 0.74 (0.53–1.03), respectively.
Of the total 1,080 HIV-uninfected WIHS participants, 604
(55.9%) had stable health insurance at the baseline visit, of
whom 328 (54.3%) had prior hypertension, of whom 289
(88.1%) had concurrent controlled hypertension and stable
health insurance, of whom 272 (94.1%) attended at least one
visit after baseline (Fig. 1). These 272 women comprised
Group C, and accrued 620.4 person-years of follow-up and
1,498 study appointments (Table 1). These women did not
markedly differ from the 842 HIV-infected women by race,
education, age at baseline, or type of health insurance (public
versus private) at baseline (all p > 0.05). However, HIV-
uninfected women had lower annual household incomes at
baseline ( p < 0.01), with 21.3% of women in the <$6,000
category compared to 13.9%.
As in the HIV-infected women, the rate of hypertension
control loss was high (33.0 per 100 person-years; 95% CI,
29.3–37.1), with most women (n = 205, 75.4%) experiencing
this outcome. Few women were censored due to missed visits
or death (n = 22, 8.1%) or maintained controlled hypertension
(n = 45, 16.5%). Coverage interruption occurred in 14.6% of
HIV-uninfected women (n = 40) at a rate of 7.6 per 100
person-years (95% CI, 5.4–10.3), compared to 8.7% of HIV-
infected women at 3.7 per 100 person-years (95% CI, 2.9–
4.7). This resulted in a larger proportion of follow-up
occurring postinterruption (14.9%, 92.3 person-years);
46.7% of postinterruption person-time was uninsured. The
median systolic and diastolic BP at visits where insurance
was reported was 122 mmHg (IQR, 112–132) and 75 mmHg
(IQR, 69–81), respectively, similar to the median systolic
(123.5 mmHg; IQR, 113–132) and diastolic (77 mmHg; IQR,
70–81) values at visits where no insurance was reported.
FIG. 2. Number of HIV-
infected women by year of
follow-up and health insur-
ance status, and cumulative
events (instances of hyper-
tension control loss) over
time.
Table 2. Estimated Effects of Health Insurance Interruption on Loss of Hypertension Control









HR 95% CI HR 95% CI HR 95% CI
Unweighted, unadjusted 1.29 0.95–1.75 1.40 1.01–1.94 1.24 0.83–1.86
Weighted (marginal structural model)a 1.37 0.99–1.91 1.47 1.04–2.09 1.39 0.88–2.21
Weighted (marginal structural model),a
censor 3 years postbreak
1.42 1.00–2.02 1.53 1.04–2.23 1.44 0.91–2.29
aAccounting for baseline confounders: site, race, age, and in HIV-infected women only, CD4 count and HIV viral load, as well as time-
varying confounders affected by prior exposure: annual household income, body mass index, and in HIV-infected women only, CD4 count
and HIV viral load.
HR, hazard ratio; CI, confidence interval.
Estimates of the effect of coverage interruption on loss of
hypertension control in HIV-uninfected women were similar
to those from HIV-infected women, although HRs were less
precise due to the smaller sample (Table 2). In Group C, as in
Groups A and B, the cumulative incidence of hypertension
control loss given coverage interruption at baseline was
higher than given the natural course. In this HIV-uninfected
group, the 6-year cumulative incidences of hypertension
control loss were 82.5% (95% CI, 72.5–88.9) given unin-
terrupted coverage and 87.6% (95% CI, 74.9–93.9) given
coverage interruption, since baseline (Fig. 3). The HR com-
paring uninterrupted coverage to the natural course was 0.78
(95% CI, 0.52–1.19).
Discussion
Our analyses demonstrate that health insurance interrup-
tion increases the hazard of hypertension control loss in both
HIV-infected (HR, 1.37, 95% CI, 0.99–1.91) and HIV-uninfected
women at risk for HIV infection (HR, 1.39; 95% CI, 0.88–2.21)
in the US. These HRs support the notion that insurance conti-
nuity maintains lower BP levels, which would be expected to
prevent downstream morbidity and mortality due to hyperten-
sion,43,44 and encourage policy efforts to expand and strengthen
coverage. In tandem with other BP-lowering interventions such
as self-monitoring and patient/provider education,45 needed to
minimize the individual and public health burdens of elevated
BP given the observed high incidences of hypertension control
loss even with insurance, our findings advocate continuous
insurance as a strategy for BP maintenance.
The substantial proportion of women who experienced
hypertension control loss is consistent with a national esti-
mate that only 52% of hypertensive patients exhibit BP
control.46 Our results are also consistent with a recent report
of high prevalence of uncontrolled hypertension among hy-
pertensive HIV patients, in which 41% of hypertensive HIV-
infected men lacked hypertension control after a median of
3.4 years of follow-up.47
A stronger effect estimate was noted when the coverage
definition included ADAP, likely reflecting that ADAP is a
source of antihypertensive medications for many uninsured
HIV patients; a break had greater consequences when women
were uninsured and also without ADAP coverage. This high-
lights another reason beyond ART access (and subsequent HIV
suppression) for policymakers to support ADAP financially–
over 6 years there would be 116 fewer instances of hypertension
control loss in 1,000 HIV-infected women with continuous
health insurance or ADAP than in women without either.
When follow-up was censored, the HR slightly increased,
suggesting a negative impact on hypertension control that is
temporally proximate to coverage interruption, and height-
ened vulnerability to losing control in the period immediately
following a break. This is consistent with losing access to
hypertension medications as a causal mechanism, and un-
derscores the need to remove administrative barriers con-
tributing to disruptions in plans providing drugs (e.g., states
requiring biannual ADAP recertification48).16
Our findings underscore a potential and previously un-
known population-level benefit on hypertension control if
additional states were to expand Medicaid, given these areas’
high numbers of low-income13 and HIV-infected49 individuals,
and encourage such action. This study dovetails with a projec-
tion that health insurance expansions will increase the propor-
tion of treated hypertensive patients by 5.1% by 2016, with
longer term reductions in cardiovascular-related events.50
HIV-uninfected women in our sample had lower house-
hold incomes while also experiencing higher crude rates of
coverage interruption and hypertension control loss; sug-
gestions of higher cumulative incidences were limited by
precision. While differences may be partly due to enrollment
criteria that are unique to HIV-uninfected women (e.g., high
HIV-risk sex or drug use) or poorer healthcare access, they also
illustrate the population’s vulnerability to insurance coverage
interruptions and loss of hypertension control, as well as the
importance of targeting interventions to this group.
Study limitations include self-reported health insurance
data and 6-monthly interval measurement that precluded
more precise information on exactly when coverage inter-
ruption and hypertension outcomes occurred, although re-
sultant biases were likely mitigated by the frequent visit
schedule. We also incorporated the unverifiable assumption
of no unmeasured confounding and assumed homogeneity
FIG. 3. Estimates of the cumulative incidences of loss of hypertension control given uninterrupted health insurance and
interruption at baseline among women with stable health insurance in the WIHS, 2005–2014. Estimates are at the reference
level of nominal covariates (site: Brooklyn or Bronx; race: African American) and the average level of continuous
covariates: age; CD4 count, and HIV viral load (Groups A and B only; there are no covariates specific to Group C). ADAP,
AIDS Drug Assistance Program; WIHS, Women’s Interagency HIV Study.
across insurance types (i.e., collapsing coverage into yes or
no), an oversimplification given WIHS evidence that HIV
suppression differs by insurance type.31 Exposure dichoto-
mization was necessary due to limited sample size. Although
our HRs suggested meaningful effects, larger studies would
allow for closer investigation of coverage continuity’s im-
pacts on hypertension control and other outcomes.
It is also worth noting that while the prognostic signifi-
cance of a point-in-time loss of hypertension control remains
largely unknown, the relatively small number of women el-
igible for the analysis coupled with a low incidence of car-
diovascular episodes precluded evaluation of a clinical event
outcome. Given strong evidence that poorly controlled
hypertension imparts cardiovascular risk,43,44 it was still
worthwhile to examine loss of hypertension control, espe-
cially since the multiple BP measurements at a single time
point provided a high degree of confidence in outcome
classification. While it would have been useful to describe the
duration of hypertension control loss in a more detailed
manner, this was not possible because the interval cohort
design of the WIHS only allows BP measurement twice an-
nually. Additional studies of insurance continuity should
evaluate cardiovascular events as an outcome, as well as car-
diovascular events downstream of uncontrolled hypertension.
Utilization of a different threshold for hypertension control,
such as the 120 mmHg target for systolic BP investigated in the
Systolic Blood Pressure Intervention Trial (SPRINT),51 may
have yielded substantially different results. Along with high-
lighting that more nuanced treatment of definitions for hyper-
tension and its control will be required in future similar
analyses if the trend continues toward unique BP targets for
different age and risk factor groups,52–55 the higher rates of
cardiovascular events and death at the 140 mmHg target (vs.
120) revealed by SPRINT further emphasize the individual and
public health significance of our findings. We used a cut point
of 140 mmHg systolic, which may be associated with higher
morbidity and mortality risk than lower thresholds.51,56,57
Study strengths include minimal missing data, rigorous
quality control of laboratory and outcome ascertainment,
and inclusion of HIV-infected and HIV-uninfected women.
Notably, HIV-infected WIHS women represent the greater
population of HIV-infected women in the US.29 However,
because data were from study participants who had contact
with healthcare, our results could be muted compared to those
from non-WIHS populations.
This work also responds to a call to report not just ‘‘always
versus never’’ contrasts,58 that is, continuously insured ver-
sus interrupted since baseline, as it is difficult to imagine an
entire population losing its coverage. Specifically, we con-
trasted continuous insurance—a hypothetical scenario at-
tainable if policy changes establish universal coverage—to
the natural course, revealing a HR of 0.74 (95% CI, 0.53–
1.03) in HIV-infected women when coverage included
ADAP. Assuming the continuously insured population rep-
resents the population continuously insured under universal
coverage, the contrast reflects and informs an intervention
that instates universal coverage.
Conclusions
This study indicates that health insurance continuity pre-
vents loss of hypertension control in key populations in the
US, an impact that may have been surmised but was here-
tofore unquantified. Interventions targeted at low-income and
HIV-infected individuals to ensure coverage stability and
access, including for ADAP, should be a policy priority.
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